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Abstract 
Background:  While there is a commercially-available vaccine for Streptococcus equi subsp. equi 
licensed for the intranasal route of administration, some equine practitioners are administering this 
vaccine orally despite a lack of evidence for its efficacy by this route of administration. 
Objectives:  To compare systemic and local immune responses following intranasal or oral 
administration of the USDA-approved, live-attenuated Streptococcus equi subspecies equi vaccine 
(Pinnacle IN®, Zoetis, Florham Park, New Jersey). 
Study Design:  Experimental, randomized clinical trial 
Methods:  Eight healthy horses with low Streptococcus equi M protein (SeM) titers (<1:1600) 
were randomly assigned to an intranasal or oral two-vaccine series.  SeM-specific serum 
immunoglobulins G (IgG) and A (IgA) and nasal secretion IgA were assessed using a 
commercially-available ELISA (Equine Diagnostic Solutions, LLC, Lexington, Kentucky) and a 
novel magnetic microsphere assay utilizing fluorescence.  A general linear mixed models approach 
was used for statistical data analysis. 
Results:  As expected, intranasal vaccinates showed substantial increases in both serum SeM-
specific IgG and IgA levels post-vaccination (P=0.0006 and P=0.007, respectively).  Oral 
vaccinates showed an increase in serum SeM-specific IgG post-vaccination (P=0.0150), though 
only one-third the magnitude of intranasal vaccinates.  Oral vaccinates showed no evidence of 
change in SeM-specific IgA post-vaccination (P=0.15). 
Main Limitations: Changes in mucosal antibody responses were not identified in this study which 
may be related to small change in antibody response, timing of sample collection, or method of 
nasal secretion collection. 
   
Conclusions:  Results indicate that intranasal or oral vaccine administration resulted in increased 
serum SeM-specific IgG, though the magnitude of response differed between routes. 
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Chapter 1 - Introduction 
Streptococcus equi subspecies equi, a gram-positive, Lancefield group C streptococci, is a 
highly contagious upper respiratory tract bacterial pathogen of horses.  In susceptible populations, 
morbidity to S. equi can reach 100% (Ainsworth and Cheetham. 2010).  Due to its high 
contagiousness and its short and long-term equine health implications, control of Streptococcus 
equi is of paramount importance to the equine industry.  Infection with S. equi begins with entry 
into the mouth or nose, where the bacteria attaches to lingual, palatine, pharyngeal, and tubal 
tonsils (Sweeney et al. 2005).  Virulence factors including exposed surface proteins are involved 
in the attachment and penetration to tonsils, followed by translocation to submandibular and 
retropharyngeal lymph nodes, and finally prevention of bacterial phagocytosis and destruction by 
neutrophils (Sweeney et al. 2005; Timoney and Kumar. 2008).   
After recovery, approximately 75% of horses develop a strong, enduring immunity that 
persists for 5 years or more (Sweeney et al. 2005).  Optimal immunity likely relies on both 
systemic and mucosal immune responses (Timoney. 2004); therefore, efficacious vaccines likely 
need to stimulate both for protection.  A non-encapsulated, live-attenuated strain of S. equi 
(Pinnacle IN®, Zoetis, Florham Park, New Jersey) has demonstrated efficacy against experimental 
challenge (Walker and Timoney. 2002).  The intranasal administration of this attenuated vaccine 
mimics natural exposure to the pathogen and thus intends to stimulate a similar immune response.  
Adverse effects have been associated with this vaccine including abscess formation at remote sites, 
development of disease, or purpura hemorrhagica (Borst et al. 2011).  Another common problem 
associated with intranasal vaccination is removal of the attenuated strain by sneeze-mediated 
expulsion of nasal secretions.  Due to these challenges, the zoonotic potential of S. equi (Breiman 
and Silverblatt. 1986), and difficulty with the intranasal route of administration, some equine 
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practitioners have adopted the oral route of vaccine administration for their equine patients.  
However, to date there is no evidence to support that oral vaccination elicits a systemic immune 
response that could potentially confer host protection to pathogen challenge. 
 Objective 
Therefore, the primary objective of this study was to compare immune responses 
following oral administration of the attenuated vaccine strain relative to that of the licensed 
intranasal route of vaccination.  We hypothesized that the attenuated vaccine strain would come 
in contact with the pharyngeal tonsils following oral administration, as occurs with natural 
infection, thereby eliciting a measurable immune response.  We monitored the systemic immune 
response by means of serum S. equi M protein (SeM) specific immunoglobulins G (IgG) and A 
(IgA), and the mucosal immune response using nasal secretion SeM-specific IgA.  Based on 
results, recommendations for the alternative route of vaccine administration can be made.  
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Chapter 2 - Literature Review 
 Streptococcus equi subspecies equi 
Streptococcus equi subspecies equi is a gram-positive, β-hemolytic, Lancefield group C 
streptococci.  It is a highly contagious upper respiratory tract bacterial pathogen and the 
causative agent of one of the most common infectious diseases of horses, known as strangles.  In 
susceptible populations, morbidity to S. equi can reach 100% (Ainsworth and Cheetham. 2010).  
Clinical signs include fever, pharyngitis, and rhinitis, followed by lymphadenopathy, subsequent 
abscess formation, and rupture of the retropharyngeal and submandibular lymph nodes.  As 
lymph nodes rupture, mucopurulent nasal discharge from the retropharyngeal lymph nodes 
which rupture into the guttural pouches or purulent drainage from the submandibular lymph 
nodes typically develops.  Lymphadenopathy may cause compression of the pharynx, larynx, or 
trachea causing significant dyspnea requiring intervention until lymph node abscess maturation 
and rupture.  This situation gives the infection its common name of “strangles.”  Predictor 
variables associated with development of strangles include mucopurulent nasal discharge, 
external abscessation, and season where strangles is more common in the spring than summer 
(Duffee et al. 2015). 
Some horses that are affected with strangles remain persistently infected in their guttural 
pouches after rupture of the retropharyngeal lymph nodes and are asymptomatic, chronic carriers 
that serve as a potential source of outbreaks.  With chronicity, guttural pouch empyema becomes 
inspissated forming chondroids which harbor the organism.  Prevalence of the development of 
carriers associated with strangles outbreaks reportedly ranges from 0.3% to 10% (Sweeney et al. 
1987; Newton et al. 1997; Waller and Jolley. 2007).  Another study that defined asymptomatic 
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carriers as being positive on nasopharyngeal wash PCR 40 days after infection reported a 
prevalence of 30% (Duffee et al. 2015). 
Less common manifestations of infection include disseminated metastatic abscesses, 
immune-mediated purpura hemorrhagica, or myositis.  Disseminated abscesses develop via 
hematogenous or lymphatic routes.  Abscesses can develop in remote lymph nodes, organs such 
as lungs, liver, kidneys, spleen, and rarely brain, heart, and joints.  Prevalence of metastatic 
abscessation development associated with strangles outbreaks range from 1.9% (Duffee et al. 
2015) and 2.7% (Sweeney et al. 1987) up to 20% (Whelchel and Chaffin. 2009).  Immune-
mediated purpura hemorrhagica is a type III immune complex hypersensitivity reaction that 
typically occurs 3-4 weeks after strangles infection or vaccine administration.  Immune 
complexes deposit within blood vessels to cause a vasculitis.  Clinical signs include ventral and 
peripheral edema, skin necrosis and sloughing, and mucosal petechial and ecchymotic 
hemorrhages.  Prevalence of purpura hemorrhagica following strangles outbreak is reported to 
range from 2% (Sweeney et al. 1987) to 6.5% (Duffee  et al. 2015).  Risk factors associated with 
purpura hemorrhagica development include pre-existing high SeM titers (>1:1600) and anemia 
(Duffee et al. 2015).  Rarely infarction of various organs including the gastrointestinal tract, 
muscles, and lungs occurs associated with purpura hemorrhagica.  Infarctive purpura 
hemorrhagica has a high fatality rate and is associated with clinical signs of muscle stiffness, 
colic, and severe pain and recumbency.  Immune-mediated myositis may also develop secondary 
to strangles infection due to cross reaction of myosin and S. equi M protein.  Typically middle-
aged Quarter horses are affected, and clinical signs include depression and rapid, severe muscle 
atrophy.   
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 Pathogenesis 
Infection with S. equi begins with entry into the mouth or nose, where the bacteria attaches 
to lingual, palatine, pharyngeal, and tubal tonsils (Timoney and Kumar. 2008).  Virulence factors 
including exposed surface proteins (SzPSe, Se73.9, and Se51.9) are involved in attachment and 
penetration to tonsils (Sweeney et al. 2005).  The organism then translocates to the submandibular 
and retropharyngeal lymph nodes that drain the tonsils.  Chemotactic factors attract neutrophils to 
the infected lymph nodes; however, other virulence factors (combination of hyaluronic acid 
capsule, antiphagocytic SeM protein, and Mac protein) prevent bacterial phagocytosis and 
destruction by neutrophils (Harrington et al. 2002; Timoney and Kumar. 2008; Timoney et al. 
2014).  Attraction of neutrophils and prevention of destruction leads to abscess formation; rupture 
of abscesses leads to dissemination.  Fever occurs 3-14 days following exposure and nasal 
shedding begins 2-3 days after onset of fever.  Elimination of nasal shedding of the organism after 
2-3 weeks coincides with the development of systemic and mucosal immune responses (Galan and 
Timoney. 1985).  Monocytes and tonsillar macrophages play a major role in S. equi clearance as 
they have bactericidal activity in the presence of convalescent antibody through organism 
interiorization and phagocytosis (Merant et al. 2011).  Pre-existing humoral and cellular immunity 
help protect against clinical disease development after exposure (Nara et al. 1983). 
 Immune response and immunity   
After recovery, 75% of horses develop a strong, enduring immunity that persists for 5 years 
or more (Sweeney et al. 2005).  SeM is highly immunogenic.  Various projects have studied the 
immune response following experimental S. equi infection.  Horse IgG subisotypes include IgGa, 
IgGb, IgGc, and IgG(T) (Sheoran et al. 1997), where IgGb is the most important subisotype with 
regard to protective immunity (Sheoran et al. 2000).  Horse IgA is present as serum or secretory 
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IgA, where serum IgA is typically a dimer (Sheoran et al. 1997).  SeM-specific serum IgGa is 
produced shortly after infection, SeM-specific mucosal IgA and IgGb are produced during acute 
and convalescent periods (Sheoran et al. 1997), and SeM-specific serum IgGb as well as serum 
IgGb to surface exposed proteins are produced late in convalescence in some horses (Timoney and 
Eggers. 1985).  Serum SeM-specific IgGb is predominant during both the acute and convalescent 
periods from weeks 3 to 28 after infection (Sheoran et al. 1997).  Serum SeM-specific IgGa is 
present from week 2 to 14 after infection (Sheoran et al. 1997).  Serum SeM-specific IgA is present 
late in infection from weeks 5 to 14 after infection (Sheoran et al. 1997).  Mucosal IgA and IgG 
are detected 1-2 weeks after infection but are much higher at 6-7 weeks after infection (Galan and 
Timoney. 1985).  Mucosal IgA was detected from weeks 3 to 28 after experimental infection where 
nasopharyngeal washes were used to collect mucosal samples (Sheoran et al. 1997).  SeM-specific 
IgGa, IgGb, and IgA were found to have opsonophagocytic activity in the presence of complement 
(Sheoran et al. 1997).  The mucosal antibodies that are produced protect against further infection 
by either preventing adhesion of the bacterium or preventing interiorization to tonsillar cells (Galan 
and Timoney. 1985; Timoney. 2004).  Optimal immunity likely relies on both systemic and 
mucosal immune responses (Timoney. 2004); therefore, efficacious vaccines likely need to 
stimulate both for protection.   
 Diagnosis 
Diagnosis of classic strangles relies on culture or polymerase chain reaction (PCR) of 
ideally purulent material.  Other samples that can be tested include nasopharyngeal lavage, 
guttural pouch lavage, or less ideally nasopharyngeal or nasal passage swab.  Nasopharyngeal 
wash PCR was found to have the highest detection rate (84%) when compared to nasal passage 
swab culture (37%) or PCR (53%) or nasopharynx swab culture (37%) or PCR (72%) (Lindahl et 
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al. 2013).  In order for culture or PCR to be positive, the horse must be shedding the bacterium 
(24-48 hours after onset of fever).  Culture will detect live organisms, while PCR, which is 
detecting the SeM protein, will not differentiate between live or dead organisms.  Guttural pouch 
endoscopy can be performed to visual enlarged retropharyngeal lymph nodes.   
Diagnosis of an asymptomatic carrier is through endoscopy to visualize guttural pouch 
empyema or chondroids followed by guttural pouch lavage culture or PCR for S. equi.  If 
endoscopy is not available, nasopharyngeal lavage culture or PCR for S. equi is indicated.   
To diagnose disease complications such as disseminated metastatic abscessation or 
purpura hemorrhagica, serology directed against SeM protein can be performed (Table 1).  The 
SeM titer is most useful to determine need for vaccination or risk of purpura hemorrhagica and to 
diagnose metastatic abscessation or purpura hemorrhagica.  Because at pre-existing high SeM 
titer is associated with development of purpura hemorrhagica following vaccination, studies have 
determined factors that are associated with horses having high titers (Boyle et al. 2009).  
Increased age, Quarter horse and other breeds compared to Thoroughbreds and warmbloods, and 
previous vaccination increased the odds of having a SeM titer >/= 1:1600 (Boyle et al. 2009).  
None of the 21 horses with an SeM titer of 1:1600 or of the 5 horses with an SeM titer of 1:3200 
at the time of revaccination developed any signs of purpura hemorrhagica (Boyle et al. 2009). 
 
Table 1:  SeM ELISA titer interpretation (Sweeney et al. 2005) 
SeM titer Interpretation (adapted from Sweeney et al. 
2005) 
Negative No previous exposure or recent (<7 days) 
exposure or vaccination. 
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1:200-1:400 (Weak positive) Recent or remote exposure or vaccination.  
Recommend recheck in 7-14 days to 
determine if recent exposure. 
1:800-1:1600 (Moderate positive) 2-3 weeks after exposure or vaccination or 
infection 6 months to 2 years previously. 
1:3200-1:6400 (High positive) 4-12 weeks after exposure or vaccination.  
Vaccination contraindicated if titer > 1:1600. 
>1:12,800 (Very high positive) Often associated with metastatic abscessation 
or purpura hemorrhagica 
 
Some researchers have called the SeM ELISA into question because an M protein in 
Streptococcus equi subsp zooepidemicus (SzM) shares 2/3 homology with SeM increasing the 
possibility of false positives with this test.  Recently an indirect ELISA (iELISA) using 2 
antigens (antigens A and C) was compared to the SeM iELISA.  This combined antigen A and 
antigen C iELISA increased sensitivity and specificity from 89.8% and 77.0%, respectively, to 
93.3% and 99.3%, respectively (Robinson et al. 2013). 
 Treatment 
Appropriate treatment depends on stage of disease.  Horses in the early stage of infection 
displaying just pyrexia and depression but no lymph node abscessation can be treated with 3 
days of antibiotic therapy.  This may prevent development of abscessation, but these horses 
remain susceptible to reinfection as they do not produce protective immunity. 
Horse with evidence of external lymphadenopathy should be treated with the aim of 
encouraging abscess maturation.  Hot packing may help with abscess maturation, or surgical 
drainage may be required.  Daily lavage of the opened abscess should be performed until 
drainage stops.  Nonsteroidal anti-inflammatories may be administered to control fever, 
inflammation, and pain associated with abscessation.  Antibiotics are contraindicated in simple 
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cases of lymphadenopathy as it suppress the bacteria within the enlarged lymph nodes but 
abscessation continues when antibiotics are discontinued. 
Horses with complications of external lymphadenopathy including dyspnea associated 
with upper airway obstruction, dysphagia, or dehydration should be treated with antibiotics 
typically penicillin and supportive care.  In cases of dyspnea, tracheostomy may be required.  In 
these complicated cases, antibiotics will help to decrease the size of abscesses and prevent 
secondary infections associated with these complications such as aspiration pneumonia.  Other 
supportive care may include nonsteroidal anti-inflammatories, intravenous fluids, or enteral 
feeding through a nasogastric tube. 
Asymptomatic, chronic carriers should be treated to eliminate the carrier state.  This may 
be accomplished through guttural pouch lavage, endoscopy and the use of memory-helical polyp 
retrieval basket through the biopsy channel, instillation of gelatin/penicillin solution into the 
affected guttural pouches, and even surgical intervention along with systemic antibiotic therapy.   
Horses with metastatic abscessation require long-term systemic antibiotic therapy and 
local treatment and drainage of abscesses if possible along with supportive care as needed.  
Horses with purpura hemorrhagica require corticosteroids to control the immune response 
associated with the disease.  Antibiotics are also indicated as purpura can develop in association 
with active S. equi infection as well as the immunosuppressive effects of corticosteroids increase 
the risk of developing secondary infection.  Supportive care should be instituted as well which 
may include nonsteroidal anti-inflammatories, intravenous fluids, and hydrotherapy and 
bandaging for peripheral edema.   
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 Control 
During an outbreak, strict quarantine, hygiene, and biosecurity are required.  Because 
pyrexia is typically the first clinical sign, rectal temperatures of all exposed horses should be 
monitored daily.  If pyrexia is detected, that horse should be quarantined and possibly treated.  
Before re-introduction to the herd after disease, testing should be performed to ensure that the 
horse is cleared of infection.  Nasopharyngeal lavage, guttural pouch lavage, or nasopharyngeal 
swab culture can be performed for detection of live S. equi.  This should be performed weekly 
for 3 weeks before the horse is deemed negative (Sweeney et al. 2005).  Endoscopy should be 
performed on any asymptomatic horses that culture positive for S. equi to detect carrier animals.   
 Prevention 
Appropriate biosecurity is important for the prevention of this highly contagious disease.  
When introducing new additions, appropriate quarantine (approximately 3 weeks) should be 
instituted.  Vaccinations are also available for prevention, but none are considered fully 
protective.   
 Commercially-available S. equi vaccines 
A non-encapsulated, modified live vaccine (MLV) (Pinnacle IN®, Zoetis, Florham Park, 
New Jersey) that is administered intranasally is available in the United States.  This vaccine 
strain is S. equi strain CF32 which was isolated from a horse with strangles in New York in 1981 
that is attenuated via N-methyl-N-nitro-N-nitrosoguanidine (NTG) treatment.  The strain is 
acapsular through the deletion of hyaluronate synthase (hasA and hasB) genes which produce the 
capsule (Walker and Timoney. 2002).  This deletion prevents the vaccine strain from reverting to 
virulence, and it can be distinguishes from the wild-type strain which forms mucoid colonies 
because the vaccine strain forms small, dry colonies on culture (Walker and Timoney. 2002).  
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The intranasal route of administration is meant to mimic natural exposure to elicit both local 
mucosal and systemic immune responses.  Efficacy studies found significant differences in 
vaccinated and controls with regard to mortality (10-15% and 60%, respectively), disease 
incidence (ruptured lymph nodes), clinical score (nasal discharge, depression, fever, labored 
breathing, abscessed lymph nodes), and leukocytosis (Fort Dodge Animal Health licensing report 
TIA number:  22740. 1997).  Complications of vaccination include development of purpura 
hemorrhagica, development of abscesses at remote sites, and possibly development of clinical 
disease with the vaccine strain.  This vaccine does not appear to be safe for horse under 1 year of 
age because four 6 month-old ponies vaccinated with Pinnacle IN® (Zoetis, Florham Park, New 
Jersey) developed retropharyngeal abscessation due to the vaccine strain following vaccination 
compared to no clinical signs in ponies over 1 year of age that were similarly vaccinated (Borst 
et al. 2011).  In this study, the vaccine strain was found to still be present in nasal swabs up to 36 
days after vaccination and in tonsil swabs up to 46 days after vaccination which is potentially 
concerning because of the potential for reversion to virulence (Borst et al. 2011).  Cursons et al. 
(2015) reported on a yearling filly and a 10 month-old filly that developed submandibular lymph 
node abscesses following vaccination with Pinnacle IN® (Zoetis, Florham Park, New Jersey).  
The infecting strains were found to be similar to the vaccine strain through genome sequencing 
(Cursons et al. 2015).   
A bacterial extract vaccine containing purified M protein antigen with aluminum adjuvant 
(Strepvax II, Boehringer Ingelheim Vetmedica, Inc, St. Joseph, Missouri) that is administered 
intramuscularly is also available in the United States.  This vaccine reportedly reduces amount and 
severity of clinical disease (Mallicote. 2015).  Complications include development of purpura 
hemorrhagica and development of abscesses at the site of injection (Hoffman et al. 1991).   
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A MLV (Equilis® StrepE, MSD Animal Health, Kempton Park, South Africa) that is 
administered by mucosal injection in the upper lip is available in Europe.  This strain is 
attenuated by the deletion of the aroA gene which affects aromatic amino acid synthesis (Kelly et 
al. 2006).  In efficacy studies, 75% protection was afforded in challenge studies (Equilis® 
StrepE Data Sheet 2014, MSD Animal Health, www.msd-animal-health.co.uk).  Complications 
of this vaccine also include development of purpura hemorrhagica, development of abscesses at 
remote injection sites, and development of clinical disease associated with the vaccine strain.  
Jacobs et al. (2000) reported efficacy against challenge in five 9-11 month-old foals and minimal 
side effects of mild swelling at the injection site for 2 weeks after vaccination.  Kemp-Symonds 
et al. (2007) reported the first 2 cases of vaccine strain-induced abscessation.  A 7 year-old horse 
developed a cervical musculature abscess at the site of another injection following vaccination, 
and a 5 year-old pony developed submandibular lymphadenopathy consistent with strangles 
following vaccination (Kemp-Symonds et al. 2007).  The infecting strain was confirmed to be 
the vaccine strain through PCR and gene sequencing (Kemp-Symonds et al. 2007). 
When comparing experimental infection with S. equi to intramuscular extract vaccination 
(Strepguard®, Intervet/Merck Animal Health, Summit, New Jersey), the serum antibody 
response to cell surface antigens differed (Velineni et al. 2015).  Another study compared 
experimental convalescent horses with intramuscularly vaccinated horses (Strepguard®, 
Intervet/Merck Animal Health, Summit, New Jersey) (Sheoran et al. 1997).  Serum SeM-specific 
IgGb and IgGa were detected 1 week after vaccination and the peak increase of both were 
significantly higher than convalescent horses.  However, mucosal IgG or IgA were not detected 
in nasopharyngeal washes of vaccinated horses (Sheoran et al. 1997).   
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One study compared the serum antibody response following vaccination with either the 
intramuscular extract vaccine (Strepguard®, Intervet/Merck Animal Health, Summit, New 
Jersey) or the intranasal modified-live vaccine (MLV) (Pinnacle IN®, Zoetis, Florham Park, 
New Jersey) and then experimental challenge (Hobo et al. 2010).  A serologic response to 
proline-glutamic acid-proline-lysine antigen with five repetitions (PEPK-5R) was tested.  The 
extract vaccine elicited a slightly higher immune response than the MLV, and after challenge, the 
immune response to PEPK-5R was significantly higher in the extract vaccine group compared to 
the MLV group (Hobo et al. 2010).  One out of three horses in the extract vaccine group and two 
out of three horses in the MLV group developed lymphadenopathy with rupture where the 
challenge strain of S. equi was identified via PCR (Hobo et al. 2010).   
 S. equi vaccines under investigation 
Many researchers have investigated other antigens, adjuvants, or delivery methods for S. 
equi vaccination as none of the commercially-available vaccines are fully protective.   An ideal 
vaccine would be 100% protective, easily administered (intramuscularly for horses), have no 
adverse effects, and be able to be differentiated from infection.  None of the commercially-
available vaccines fulfill these ideal requirements.   
Flock et al. (2004) used S. equi extracellular antigens including two fibrinogen binding 
proteins (FNZ and SFS) and an IgG, serum albumin, and α2 macroglobulin-binding surface 
protein (EAG) with or without adjuvant (E. coli heat-labile enterotoxin B) as a vaccination.  
These antigens with or without adjuvant were administered intranasally, subcutaneously, or both.  
Only horses receiving the antigens with adjuvant by both the intranasal and subcutaneous routes 
exhibited high mucosal antigen-specific IgA, while horses that received the three antigens with 
adjuvant by either the intranasal route alone or both intranasal and subcutaneous routes had 
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elevated serum antigen-specific IgG (Flock et al. 2004).  No adverse effects to this vaccine were 
noted, but challenge was not performed to determine the protective nature of the immune 
response elicited.   
Recombinant S. equi proteins were used as intranasal antigens in mice to determine the 
immune response (Flock et al. 2006).  Collagen-binding protein (CNE) and collagen-like protein 
(ScIC) vaccinations elicited protective antibodies after experimental infection (Flock et al. 
2006).  Fibrinonectin-binding protein (FNEB) did not elicit protective antibodies after 
experimental infection (Flock et al. 2006).  A synergistic response was found with co-
administration of CNE and EAG to elicit protective antibodies (Flock et al. 2006).  These 
antigens were chosen to test in mice based on immune response to these antigens in serum from 
previously infected horses (Flock et al. 2006). 
Waller et al. (2007) investigated these recombinant protein (EAG, CNE, and ScIC) as 
vaccine antigens in horses against experimental challenge.  Nine 6 month-old ponies were 
vaccinated both intramuscularly and intranasally and seven 6 month-old ponies were used as 
unvaccinated control.  Vaccination elicited serum and mucosal IgG responses but low mucosal 
IgA (Waller et al. 2007).  After challenge, both vaccinated and control ponies displayed signs of 
clinical disease but disease severity was significantly reduced in vaccinated ponies (Waller et al. 
2007). 
Another group of surface proteins was investigated in horses exposed to S. equi infected 
horses to determine the immune response and protective capability (Timoney et al. 2007).  One 
vaccine contained the antigens SzPSe, Se73.9, Se51.9, Se44.2, and Se46.8 and the other 
contained the antigens SeM, Se44.2, Se75.3, Se42.0, Se110.0, and Se18.9.  Antibody responses 
were found to all proteins except Se51.9 and CNE, and antibodies specific to SeM and SzPSe 
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were higher than other antibodies and persisted through 200 days after vaccination (Timoney et 
al. 2007).  These antibody responses however did not afford protection against exposure to S. 
equi-infected horses (Timoney et al. 2007). 
An intramuscular multigene deletion strain, where sagA, hasA, seM, aroB, pyrC, and 
recA genes were deleted, was investigated (Robinson et al. 2015).  Deletion of sagA, hasA, and 
seM genes was performed to reduce ability to resist phagocytosis and improve vaccine safety.  
Deletion of sagA caused loss of production of the hemolytic toxin, streptolysin S (SLS) making 
the colonies non-hemolytic as well as making the colonies less able to colonize tracheal mucosa 
(Robinson et al. 2015).  Deletion of hasA resulted in non-encapsulated colonies susceptible to 
phagocytosis.  Deletion of aroB and pyrC reduced the ability to produce aromatic amino acids 
and pyrimidines; and deletion of recA reduced the environmental persistence by increasing the 
susceptibility to ultraviolet light (Robinson et al. 2015).  Nine ponies were vaccinated 
intramuscularly on Day 0 and seven ponies were revaccinated on Day 56.  Nine ponies were 
unvaccinated controls.  All ponies were challenged on Day 52 after the second vaccine.  Five of 
the nine vaccinated ponies developed injection site abscesses caused by the vaccine strain where 
two were removed from the study.  Six out of nine control ponies were pyrexic following 
challenge whereas none of the seven vaccinated ponies were significantly febrile (Robinson et al. 
2015).  Nine out of nine control ponies had lymph node abscesses, whereas only one of the seven 
vaccinated ponies had a lymph node abscess (Robinson et al. 2015). 
Cholera toxin (CT) as an adjuvant for intranasal administration of the immunogenic 
peptide (SeMF3) was evaluated in ponies in a challenge model (Sheoran et al. 2002).  Cholera 
toxin is immunogenic and enhances uptake by mucosal-associated lymphoid tissue (MALT) 
(Sheoran et al. 2002).  Ponies vaccinated with CT-SeMF3 developed higher serum SeMF3-
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specific IgGb and nasal SeMF3-specific IgA than control horses; however, when exposed to 
experimentally infected horses, vaccination did not confer protection (Sheoran et al. 2002). 
A sucrose acetate isobutyrate (SAIB)-based delivery system for intranasal aerosol 
administration of an immunogenic peptide (SeMF3) was evaluated (Nally et al. 2001).  Eleven 
horses were vaccinated with the SeMF3 with SAIB, and seven horses were vaccinated with just 
SeMF3 without SAIB at day 0 and week 4.  Horses vaccinated with SeMF3 with SAIB had 
significantly elevated mucosal IgA, IgGa, and IgGb as well as serum IgA and IgGb compared to 
horses just vaccinated with SeMF3 without SAIB (Nally et al. 2001).   
A poly-ε-caprolactone (PCL)-based nanoparticle delivery system for intranasal 
administration was evaluated in mice (Florindo et al. 2009).  The PCL nanoparticles are 
biodegradable, increase the concentration of antigen to promote its interaction with antigen 
presenting cells, and protect antigens from proteolytic enzymes so they are useful as a vaccine 
delivery system especially to the MALT (Florindo et al. 2009).  The nanoparticles used were 
coupled with either mucoadhesive polymers (alginate or chitosan) or adsorption enhancers 
(spermine or oleic acid) to act as carriers for S. equi surface proteins.  Mice vaccinated with PCL 
nanoparticles with especially mucoadhesive polymers had more robust systemic IgG and 
mucosal IgA than mice vaccinated with free antigen only (Florindo et al. 2009).  PCL 
nanoparticles are a potential delivery system for intranasal vaccinations. 
Two positively charged delivery systems, liposomes and chitosan nanoparticles, with S. 
equi extracts for intranasal administration were evaluated in mice (Figueiredo et al. 2012).  
Systemic IgG with both Th1- and Th2-mediated immune responses were elicited by both 
delivery systems; while only the chitosan nanoparticle delivery system elicited mucosal IgA 
response (Figueiredo et al. 2012). 
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 Stimulation of mucosal-associated lymphoid tissue  
Many practitioners are adopting the oral route of administration for the MLV (Pinnacle 
IN®, Zoetis, Florham Park, New Jersey) despite approval only for the intranasal route of 
administration.  Intranasal administration can be difficult (Grogan and McDonnell. 2005) and 
may result in expulsion of the vaccine strain.  The oral route of immunization is intriguing to 
stimulate mucosal-associated lymphoid tissue (MALT).  The MALT of the upper respiratory 
tract blocks attachment and penetration of microbial pathogen through antibody and cellular 
responses.  Nonspecific cellular immunity of the MALT includes complement, enzymes, and 
neutrophils and macrophages (Jakobsen and Jonsdottir. 2003).  Membranous microvillus (M) 
cells overlie lymphoid tissue of inductive sites such as the tonsils in the pharynx and Peyer’s 
patches of the jejunum and ileum (Kumar et al. 2001).  M cells are intimately associated with 
antigen-presenting cells including dendritic cells, lymphocytes, and macrophages so that antigens 
can be rapidly transported to the underlying lymphoid tissue (Holmgren and Czerkinsky. 2005).  
Activation of M cells in the MALT causes homing of B cells to mucosal sites and production of 
specific IgA as well as systemic antibody production (Kumar et al. 2001).  Secretory IgA is the 
predominant antibody involve in mucosal immunity, but IgM and IgG also contribute (Holmgren 
and Czerkinsky. 2005).  Nasal- and bronchial-associated lymphoid tissue may be stimulated by 
gut-associated lymphoid tissue antigen presentation as they are all part of MALT (Wilkie. 1982).  
Oral administration of the non-encapsulated, live-attenuated S. equi vaccine (Pinnacle IN®, 
Zoetis, Florham Park, New Jersey) may induce M cells overlying tonsils in the pharynx.   
Wallace et al. (1995) compared the results of horses that were orally or intraperitoneally 
vaccinated with killed S. equi to non-immunized horses that were challenged with live virulent S. 
equi.  Orally vaccinated horses were not as febrile or as sick as control, non-immunized horses, 
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but intraperitoneally vaccinated horses did not become febrile or anorexic (Wallace et al. 1995).  
Only 2/4 intraperitoneally vaccinated horses developed submandibular abscessation, while 4/4 
orally vaccinated horses developed submandibular abscessation although not to the degree of 
control horses (Wallace et al. 1995).  Mucosal and systemic IgA and IgG were highest after 
challenge in the intraperitoneal group (Wallace et al. 1995). 
Oral vaccinations have been used in other species to stimulate MALT.  Use of the oral 
poliovirus vaccine established 99% eradication as it induced both systemic and mucosal 
immunity especially in the intestines where the virus multiplies and contributes to transmission 
(Behrend et al. 2014).  An attenuated, gamma-irradiated Brucella neotomae administered orally 
to mice stimulated serum IgG and IgM, mucosal IgG, IgM, and IgA, and antigen-specific T 
lymphocytes capable of secreting interferon (IFN)-γ and tumor necrosis factor (TNF)-α (Dabral 
et al. 2014).  This Brucella vaccine was protective against intraperitoneal and intranasal 
challenge compared to control mice (Dabral et al. 2014).  Piglets that were immunized with oral 
ovalbumin (OVA) and adjuvant produced significantly more anti-OVA IgG, IgA, and IgM 
compared to OVA alone and control (Pasternak et al. 2014).  This response indicated a 
successful systemic immune response to a mucosally-administered vaccine. 
 Microsphere immunoassays 
Microsphere immunoassays (MIA) utilize fluorescent principles to detect analytes of 
interest.  The microspheres (MagPlex® microspheres, Luminex Corp., Austin, Texas) are color-
coded with internal fluorescent dye (“region”) allowing for utilization of multiple microspheres 
for the possibility of multiplexing an assay.  In addition to color-coding, the microspheres are 
magnetized with internal iron particles containing magnetite.  (Angeloni et al. 2016)  The 
microspheres are coupled with proteins or oligonucleotides, and after incubation with samples, 
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detection antibodies with fluorescence can be measured for the analyte of interest.  The analyzer 
(Luminex Magpix®, Luminex Corp., Austin, Texas) utilizes two light emitting diodes (LED) to 
excite fluorescence of the microsphere and a fluorescent dye.  A red LED (511 nm) excites 
internal fluorescence of the microsphere itself, and a green LED (621 nm) excites fluorescent 
dye, typically phycoerythrin (PE).  A charge-coupled device (CCD) imager then detects each 
individual microsphere and quantifies fluorescence of the dye in mean fluorescence intensity 
(MFI) (luminexcorp.com).  A positive MFI response is 2 standard deviations above the negative 
control or background MFI (Angeloni et al. 2013). 
 Microsphere coupling 
Proteins or immunoglobulins can be covalently bound to microspheres by a carbodiimide 
reaction as described by Angeloni, et al (2016).  Carboxyl groups on the surface of microspheres 
are activated with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) 
reagent.  In the presence of sulfo-N-hydroxysulfosuccinimide (sulfo-NHS), this reaction forms a 
reactive sulfo-NHS-ester intermediate.  The primary amine of the coupling molecule (antibody, 
protein) replaces the reactive intermediate and forms a covalent amide bond with the 
microsphere. 
Immunoassays can be performed using indirect serologic assays, capture sandwich 
assays, or competitive assays depending on the capture molecule used and the analyte to be 
detected and measured. 
 Advantages of microsphere immunoassays 
Compared to conventional assays such as ELISA and western blot (WB), microsphere 
immunoassays are advantageous because less sample volume is required, less time and cost are 
associated with analysis, greater sensitivity is possible with lower limits of detection and a 
 20 
broader range of quantification, and the ability to multiplex an assay is possible (Christopher-
Hennings et al. 2013; Baker et al. 2012).  Compared to qualitative or semi-quantitative assays, 
the MIA can be quantitative by comparing sample MFI to standard curves.  Because the color 
coding of the microsphere represents different “regions,” these microsphere immunoassays can 
be multiplexed to allow to for potentially measuring up to 100-500 different analytes 
(luminexcorp.com).  The major limitation for microsphere immunoassays is lack of veterinary 
species-specific antibodies to antibodies, as well as cytokines and chemokines. 
 Development of standard curves for quantitative measurements 
A standard curve can be developed by utilizing a sample with a known analyte 
concentration.  The known sample is diluted to known concentrations.  For example, with a 
serum sample with a known IgG quantity of 14.6 mg/ml (Horse reference serum, Bethyl 
Laboratories, Montomery, Texas), 1:2 dilutions can be made to have expected concentrations of 
0 ng/ml, 1.56 ng/ml, 3.12 ng/ml, 6.25 ng/ml, 12.5 ng/ml, 25 ng/ml, 50 ng/ml, and 100 ng/ml 
(Table 2).  MFI is measured for each of these standard dilution samples, and then analysis 
software can convert the measured MFI into concentrations in ng/ml by using a non-linear curve 
fitting method.  A common non-linear curve fitting method used is a five-parameter logistic 
(5PL).  These non-linear curve fitting methods plot a log-linear relationship between MFI and 
analyte concentration to develop a sigmoidal response.  The 5PL can allow for a degree of 
asymmetry associated with instrumentation and assay effects.  Data fit to a 5PL are in the form:  
 y = b + {(A – B) / [1 + (x/c)D]E} 
where: A=estimated response at infinite analyte concentration; B=estimated response at 
zero analyte concentration; c=concentration at sigmoidal inflection point; D=slope factor; and 
E=asymmetry factor. (Bates and Watts. 1988) 
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When using a fluorescence imager like the Luminex Magpix® (Luminex Corp., Austin, 
Texas), analyst software (Milliplex®, EMD Millipore, Billerica, Massachusetts) generates a 
standard curve using a 5PL.  Once a standard curve is established, the unknown samples’ MFI 
can be plotted on the curve to determine a concentration in ng/ml (Figure 1). 
 
Table 2:  Data from serum with known IgG concentrations (ng/ml) used to generate a standard 
curve using Milliplex® analyst software (EMD Millipore, Billerica, Massachusetts).  
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Figure 1:  Standard curve generated using Milliplex® analyst software (EMD Millipore, 
Billerica, Massachusetts) 
 
 
 Microsphere immunoassays utilized in equine veterinary medicine 
Microsphere immunoassays have been developed to quantify equine cytokines with a 
multiplex assay.  Wagner and Freer (2009) developed a multiplex assay for analysis of equine 
interleukin (IL)-4, IL-10, and IFN-α.  These cytokines were coupled to three different bead 
regions.  Compared to ELISA, the multiplex assay had between 13- to 150-fold improved 
sensitivity (Wagner and Freer. 2009).  More recently a multiplex for six cytokines was described 
(Hall et al. 2015).  This assay detected IL-2, IL-4, IL-6, IL-10, IFN-γ, and TNF-α with good 
sensitivity (ranging from 1.9 to 40.8 pg/ml) and low cross-reactivity (ranging from 0.1-15%) 
(Hall et al. 2015). 
Microsphere immunoassays have been developed to detect serologic responses to a 
variety of equine diseases including West Nile virus (WNV) (Balasuriya et al. 2006), flavivirus-
associated neurologic diseases (Beck et al. 2015), equine viral arteritis (Go et al. 2008), African 
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horse sickness (Sanchez-Matamoros et al. 2015), Lyme disease (Wagner et al. 2011), and 
Hendra virus (McNabb et al. 2014).  An MIA incorporating recombinant WNV envelope protein 
(rE) was found to have diagnostic sensitivity and specificity (99.3% and 97.4%, respectively) 
compared to plaque reduction neutralization test (PRNT) (Balasuriya et al. 2006).  Recombinant 
WNV nonstructural proteins (rNS) 1, 3, and 5 MIA were less sensitive (0-48.0%) (Balasuriya et 
al. 2006).  The rE MIA is advantageous compared to the PRNT because it is more convenient, 
rapid, and does not use live virus and would be useful for large scale surveillance.  A serologic 
multiplex assay for flavivirus-associated neurologic disease in horses including WNV, Japanese 
encephalitis virus (JEV), and tick-borne encephalitis virus (TBEV) was compared to virus 
neutralization titers (VNTs) (Beck et al. 2015).  The envelope (E) protein of flaviviruses is 
highly immunogenic and was used as either soluble ectodomain of E (sE) or envelope domain III 
(EDIII) for covalently binding to microspheres.  A positive TBEV.EDIII signal indicated 
infection of a horse with TBEV.  A positive WNV.EDIII or JEV.EDIII signal could indicate 
infection with WNV or JEV infection.  These findings indicate no cross reactivity of EDIII 
during TBEV infection and slight cross reactivity of EDIII between JEV and WNV (Beck et al. 
2015).  An MIA detecting equine arteritis virus (EAV) antibodies was compared to VNT (Go et 
al. 2008).  Microspheres coupled with partial glycoprotein (GP) 555-98 had a sensitivity and 
specificity of 93.1% and 93.9% compared to VNT.  The MIA results correlated significantly to 
VNT; but sera with low antibody titers (1:4 and 1:8) gave false negative results on MIA 
indicating that the MIA can only detect higher titers (>/= 1:16) to EAV reliably (Go et al. 2008).  
An MIA to detect African horse sickness (AHS) anti-viral particle (VP) 7 antibodies was 
developed and compared to commercial ELISA and lateral flow assay (LFA) kits for detection of 
anti-VP7 antibodies (Sanchez-Matamoros et al. 2015).  The MIA was found to have a lower 
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limit of detection compared to commercial kits indicating it is more sensitive, and the MIA had 
similar specificity to the ELISA while the LFA was unreliable (Sanchez-Matamoros et al. 2015).  
A multiplex MIA utilizing three outer surface proteins (Osp) of Borrelia burgdorferi was 
developed to determine vaccination versus early or chronic infection (Wagner et al. 2011).  
OspC antibodies were found during early infection and OspF antibodies were found with chronic 
infection (Wagner et al. 2011).  OspA antibodies are found with vaccination as in humans.  
Compared to the “relative” gold standard of WB, the multiplex MIA had improved sensitivity 
with antibody detection by the MIA in pg/ml compared to the WB in µg/ml (Wagner et al. 
2011).  The MIA provided a quantitative measurement compared to WB which would be useful 
for treatment response; and the MIA is more specific than quantitative ELISA tests.  Lastly, an 
MIA for Hendra virus was developed and compared to ELISA and VNT (McNabb et al. 2014).  
A recombinant glycoprotein (sG) which is more soluble was coupled to microspheres.  The MIA 
was found to be sensitive and specific with exception to Nipah virus (McNabb et al. 2014). 
     
 
 
  
 25 
Chapter 3 - Materials and Methods 
 Subject selection and treatment allocation 
Eight healthy adult horses belonging to the Kansas State University College of Veterinary 
Medicine (CVM) teaching herd were used for this study.  Horses in the teaching herd were closed 
to contact with outside horses throughout the course of investigation.  The decision to use CVM-
owned horses was twofold.  Horses considered for study were members of the CVM teaching herd 
for a minimum of 2 years, which assured that they did not suffer from S. equi infection or receive 
vaccination prior to investigation.  Additionally, it was preferred that CVM horses were used for 
to avoid the potential for adverse reaction (e.g. purpura hemorrhagica) from occurring in privately-
owned horses.  Ages ranged from 5-23 years (mean = 15 years) with body weights between 386-
603 kg (mean = 526 kg) in horses selected for investigation.  These horses were randomly assigned 
to receive either Streptococcus equi subsp. equi (Pinnacle IN®, Zoetis, Florham Park, New Jersey) 
vaccination by the intranasal or oral route (n = 4 horses each).  Horses received initial vaccination 
on Day 0, and a booster vaccination 3 weeks later on Day 21, consistent with manufacturer 
guidelines (Figure 3).  Horses were maintained in individual stalls for 3 days following vaccination 
treatment to reduce the potential for nose-to-nose contact with any other horses following 
vaccination (Harms et al. 2014).  After being housed individually, horses were maintained in a 
stall with run environment.   
For the duration of the experiment, horses received 2% of their body weight in prairie grass 
hay daily with water available free choice and concentrate supplementation as needed.  No feeding 
changes were made as a component of this investigation; horses were fed and maintained following 
routine management of the teaching herd of horses at Kansas State University College of 
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Veterinary Medicine.  Approval for this project was granted by the KSU Institutional Animal Care 
and Use Committee (IACUC #3285.1). 
 Inclusion criteria and sample collection 
Consistent with CONSORT vaccine trial guidelines, thirteen CVM teaching herd horses 
were examined for eligibility.  Inclusion criteria for this study included horses younger than 25 
years of age, determined to be healthy based on physical examination and baseline blood work 
(complete blood count and serum biochemistry), and that had a Streptococcus equi M protein 
(SeM) titer <1:1600 considered to be immunologically naïve with no history of previous 
vaccination or exposure/infection in at least the previous 24 months.  The decision for selecting 
horses that had a SeM protein titer of <1:1600 was based on the current standard of practice in 
accordance with the American College of Veterinary Internal Medicine S. equi consensus 
statement (Sweeney et al. 2005).  Eight out of thirteen horses were selected to be included in the 
vaccine trial and were randomly allocated to receive either intranasal or oral vaccination (Figure 
2).  
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Figure 2:  Experimental animals 
 
 
Host immunity was assessed via systemic and local SeM-specific humoral immune 
responses measured prior to and after vaccination.  Recall that vaccine was administered by 2 
different mucosal routes; consistent with previous equine studies aimed at detection of humoral 
immune activation, a detectable level of antibody secretion present in nasal secretions was 
expected by 2 weeks following vaccination (Nelson et al. 1998).  Also, based on known kinetics 
of primary and anemnestic host immune responses, a 4 week sampling interval following booster 
vaccination was selected to measure a serum immunoglobulin response (Nelson et al. 1998; 
Tizard. 2013).  Therefore, at two and four weeks post-booster vaccination, nasal secretion and 
serum samples were obtained from each horse (Figure 3).  Whole blood and serum were collected 
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via jugular venipuncture.  Samples were centrifuged (3700 rpm for 10 minutes), aliquoted, and 
frozen at -80 degrees C until analysis. 
 
Figure 3:  Experimental timeline 
 
 
For collection of nasal secretion samples, horses were sedated with xylazineb (0.5 mg/kg 
IV).  A 4x4 gauze square was prepared as the nasal secretion collection device by rolling it 
cylindrically and applying an adhesive strip for detainment.  The gauze was placed in the ventral 
nasal meatus of each horse, approximately 2 inches from the nostril opening and left in place for 
20 minutes to allow for absorption of nasal secretions.  This procedure was adapted from that 
described in horses (Nelson et al. 1998) and cattle (McKercher et al. 1973) to collect undiluted 
nasal secretions.  The gauze square was then placed in a 50 mL conical tube.  Once transported 
back to the laboratory, samples were spun down (2000 rpm for 30 minutes) to concentrate 
secretions.  The collected nasal secretions were aliquoted and frozen at -80 degrees C until 
analysis. 
Complete blood count and serum biochemistry samples were conducted at the clinical 
pathology laboratory at Kansas State University Veterinary Diagnostic Laboratory, and titers for 
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serum IgG against SeM were quantified using an ELISA assay (Equine Diagnostic Solutions, LLC, 
Lexington, Kentucky). 
Serum and nasal secretion samples were tested for SeM-specific IgA immunologic 
response to vaccination using magnetic microspheres in a modified sandwich ELISA method 
described below. 
 Protein coupling to magnetic microspheres 
Carboxylated magnetic microspheres (microsphere bead 48) were coated with 
Streptococcus equi subsp. equi M protein via a carbodiimide reaction (Figure 4: A).  The protocol 
was supplied by Luminex® laboratories (Luminex Corp., Austin, Texas), as previously reported 
(Baker et al. 2012) and used 5 µg of recombinant protein (kindly provided courtesy of Dr. John 
Timoney, Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky) per 
1x106 microspheres.  The concentration of 5 µg/1x106 microspheres was used based on titrations 
of 2.5 µg, 5 µg, and 10 µg/1x106 microspheres using a negative serum sample (pre-vaccination 
SeM-specific IgG titer of 1:800) and a positive serum sample (post-vaccination SeM-specific IgG 
titer of 1:6400) (Figure 5).  
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Figure 4:  Microsphere labeling.  Magnetic microspheres coated with SeM protein (A).  
Experimental samples (B) incubated with microspheres.  Analyte detection with a secondary goat 
anti-horse IgA antibody (C) and detection PE-conjugated donkey anti-goat IgG (D). 
 
 
Figure 5:  M protein coupling titration.  Negative pre-vaccination serum sample and positive post-
vaccination serum sample used for three different M protein concentration (2.5 µg/1x106 
microspheres, 5 µg/1x106 microspheres, and 10 µg/1x106 microspheres). 
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Protein coupling to microspheres was confirmed by comparing pre-coupling M protein 
solution to post-coupling microsphere supernatant to a bovine serum albumin (BSA) standard 
curve (Figure 6).  A BSA standard sample (2 mg/ml) (Thermo Fisher Scientific Inc., Rockford, 
Illinois) was diluted to known concentrations: 0 µg/ml, 50 µg/ml, 100 µg/ml, 200 µg/ml, 400 
µg/ml, 600 µg/ml, 800 µg/ml, 1000 µg/ml, 1200 µg/ml, and 1400 µg/ml.  Each standard dilution 
and sample (pre-coupling M protein solution and post-coupling microsphere supernatant) was 
aliquoted (50 µL) in duplicate wells to a flat, clear-bottom 96 well plate.  A working solution 
(Thermo Fisher Scientific Inc., Rockford, Illinois) of 1 part Reagent A (containing sodium 
carbonate, sodium bicarbonate, bicinchoninic acid (BCA), and sodium tartrate in 0.1M sodium 
hydroxide) and 49 parts Reagent B (4% cupric sulfate) (1:50 dilution) was made, and 200 µl of 
this working solution was added to each well.  This method uses the reduction of Cu+2 to Cu+1 by 
the biuret reaction.  Detection of the Cu+1 is by chelation of the reagent containing two molecules 
of BCA with one cuprous ion resulting in a purple-colored reaction (Pierce BCA Protein Assay 
Kit, thermofisher.com).  The plate was incubated in the dark at room temperature for 1 hour to 
allow for this reaction to occur.  The plate was then read on a spectrophotometer at A550 nm.  The 
standard curve (Figure 6) was generated with the linear slope-intercept equation:  
y = 0.0001x + 0.1203, 
where y = absorbance and x = concentration (µg/ml) 
The pre-coupling M protein solution had an absorbance of 0.243 resulting in a 
concentration of 1227 µg/ml (1.2 mg/ml), and the post-coupling M protein solution had an 
absorbance of 0.147 resulting in a concentration of 267 µg/ml (0.267 mg/ml).  The binding 
efficiency was found to be 77.8% and confirmed coupling of the M protein to the microspheres. 
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Figure 6:  BSA standard curve  
 
 
The SeM protein-specific IgA assay as described below was validated by using a negative 
control of bovine serum and a positive control of a horse with a robust response to vaccination 
(serum SeM-specific IgG titer of 1:6400).  Mean fluorescence intensities (MFI) were measured 
and considered relative SeM-specific IgA quantifications.  Despite background MFI in the pre, 2-
week, and 4-week post vaccination serum or nasal secretions samples, assessing both pre and post 
MFI measurements for each sample allowed for appropriate comparison and statistical analysis.  
MFI is not meant to be a measurement of absolute immunoglobulin concentration and cannot be 
correlated to immunoglobulin concentration at this point. 
 Quantitation (in MFI) of SeM protein-specific IgA 
A 96 well plate map was prepared for replicate dilutions of experimental serum and nasal 
secretion samples.  Dilutions used for both nasal secretion and serum samples were optimized at 
approximately 1:50 for SeM protein-specific IgA detection.  A working solution of microspheres 
was prepared in phosphate-buffered solution (PBS) to allow for 5000 microspheres per well and 
y = 0.0001x + 0.1203
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50 µL per well.  SeM protein-coated Region 48 microspheres were incubated with serum or nasal 
secretion samples (Figure 4: B). 
Serum or nasal secretion samples, including a blank negative control, and microsphere 
solution were aliquoted into each of the appropriate wells at 50 µL per well each.  The plate was 
then sealed, protected from light, placed on a plate shaker, and allowed to incubate overnight at 4 
degrees C.  The plate was then washed by placing it in the plate magnet for 1 minute, decanting 
the supernatant, and resuspending the microspheres in each well with 100 µL PBS.  The wash step 
was repeated twice.  The microspheres were resuspended out of the plate magnet with 50 µL PBS 
per well.  A secondary antibody solution was prepared to allow for 50 µL per well using goat anti-
horse IgA (Bethyl Laboratories Inc., Montgomery, Texas) at a concentration of 4 µg/mL (Figure 
4: C).  The plate was again sealed, protected from light, placed on a plate shaker, and allowed to 
incubate for 1 hour.  The plate was washed again 3 times.  A detection antibody solution was 
prepared to allow for 50 µL per well using pycoerythrin-conjugated donkey anti-goat IgG (Thermo 
Fisher Scientific Inc., Rockford, Illinois) at a concentration of 4 µg/mL (Figure 4: D).  The 
concentration of 4 µg/ml was chosen based on standard curve titrations using 1 µg/ml, 5 µg/ml, 
and 10 µg/ml (Figure 7).  The plate was incubated similarly for 30 minutes.  The plate was washed 
three times and the microspheres were resuspended one final time with 100 µL of PBS per well.   
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Figure 7:  Detection donkey anti-goat IgG antibody titrations of 1 µg/ml, 5 µg/ml, or 10 µg/ml 
using an IgG standard curve. 
 
 
The data acquisition protocol was analyzed using the Luminex MagPix® (Luminex Corp., 
Austin, Texas).  The MFI reported by the Luminex MagPix® (Luminex Corp., Austin, Texas) were 
used as a measure of relative IgA quantification for each sample. 
 Statistical Analysis 
Each of the responses, namely serum IgG SeM titers, as well as serum and nasal secretion 
SeM-specific IgA (measured in MFI) was expressed in the natural log scale and fitted with a 
general linear mixed model. The linear predictor in the model included the fixed effects of 
treatment (oral vs. intranasal administration), time (pre-vaccination and post-vaccination time 
point) and their 2-way interaction. The random effect of horse nested within treatment was fitted 
to the model to identify the experimental unit for treatment and the unit of repeated observations 
over time.   
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Kenward Roger’s procedure was used to estimate degrees of freedom and adjust estimated 
standard errors.  Model assumptions were evaluated using externally studentized residuals and 
were considered to be reasonably met. 
Statistical models were fitted using the GLIMMIX procedure of SAS (SAS Version 9.4, 
SAS Institute, Cary, North Carolina) implemented using Newton-Raphson with ridging as the 
optimization technique. Estimated least square means and 95% confidence intervals are presented 
in the original scale of the data. Relevant pairwise comparisons were conducted using Bonferroni 
adjustment, as appropriate in each case to avoid inflation of Type I error rate due to multiple 
comparisons. 
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Chapter 4 - Results 
Immediately prior to the start of the study, there was no evidence for differences in serum 
IgG SeM titers (Equine Diagnostic Solutions, LLC, Lexington, Kentucky) between horses 
assigned to receive intranasal or oral vaccination (Figure 8; P=0.83); neither was there any 
evidence for differences in relative SeM-specific IgA expression (in MFI) in serum or nasal 
secretions between groups (Figures 9 and 10; P=0.93 and P=0.37, respectively).  This is consistent 
with the expectation that horses recruited for this pilot study were previously unvaccinated and 
immunologically naïve to S. equi. 
Two weeks following vaccination, an increase in serum SeM-specific IgA (in MFI) was 
apparent for intranasally-vaccinated horses only (Figure 9; P=0.0068); in turn, horses vaccinated 
through the oral route showed no evidence of changes in serum SeM-specific IgA (Figure 9; 
P=0.1504).  Moreover, serum SeM-specific IgA levels by 2 weeks after vaccination were greater 
for horses vaccinated via the intranasal route than those vaccinated by the oral route (Figure 9; 
P=0.03).  Regarding nasal secretion of SeM-specific IgA, neither group showed any evidence for 
changes from baseline to 2 weeks after the vaccine series (Figure 10; P=0.627). 
By 4 weeks following completion of the 2-dose vaccination series, all vaccinated horses 
showed a significant increase in serum IgG SeM titer (Equine Diagnostic Solutions, LLC, 
Lexington, Kentucky) regardless of route of vaccination (Figure 8; P=0.0132); however, the 
increase was substantially greater for horses vaccinated by the intranasal route (P=0.0006) 
compared with those vaccinated orally (Figure 8; P=0.0150).  The magnitude of the increase in 
IgG SeM titer relative to baseline was estimated at approximately 10-fold for the intranasally-
vaccinated horses, and at approximately 3-fold for the orally vaccinated horses. 
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Figure 8:  Least square mean estimates (and corresponding 95% confidence intervals) of serum 
IgG SeM titer (Equine Diagnostic Solutions, LLC, Lexington, Kentucky) at baseline prior to 
vaccination (week 0) and 4 weeks following a 2-dose vaccine series (week 7) for horses 
vaccinated via intranasal (purple diamond symbols) or oral (red cross symbols) routes.  Arrows 
indicate time of vaccine administration.  x,y Different letters indicate differences (P<0.05) from 
baseline to 7 weeks into the study (i.e. 4 weeks post-booster) within each vaccination group.  a,b 
Different letters indicated difference (P< 0.05) between intranasal and oral vaccinates at 7 weeks 
into the study.  Point estimates were jittered horizontally to allow for clear visualization. 
 
Figure 9:  Least square mean estimates (and corresponding 95% confidence intervals) of serum 
SeM-specific IgA (in MFI) at baseline prior to vaccination (week 0) and 2 weeks following a 2-
dose vaccine series (week 5) for horses vaccinated via the intranasal (purple diamond symbols) 
or oral (red cross symbols) routes.  Arrows indicate time of vaccine administration.  a,b Different 
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letters indicated difference (P< 0.05) between intranasal and oral vaccinates at 5 weeks into the 
study.  Point estimates were jittered horizontally to allow for clear visualization. 
 
Figure 10:  : Least square mean estimates (and corresponding 95% confidence intervals) of nasal 
secretion SeM-specific IgA (in MFI) at baseline prior to vaccination (week 0) and 2 weeks 
following a 2-dose vaccine series (week 5) for horses vaccinated via the intranasal (purple 
diamond symbols) or oral (red cross symbols) routes.  Arrows indicate time of vaccine 
administration.  Point estimates were jittered horizontally to allow for clear visualization. 
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Chapter 5 - Discussion 
In the current report, horses were vaccinated with a USDA-approved, live-attenuated S. 
equi vaccine (Pinnacle IN®, Zoetis, Florham Park, New Jersey) either via the licensed intranasal 
route or via the oral route.  Results confirmed that horses vaccinated using the licensed intranasal 
route had a substantial increase in both serum SeM-specific IgG and IgA antibody levels post-
vaccination.  Although a significant mean increase in IgG SeM titers were observed, it was noted 
that a considerable amount of variability was observed amongst horses, probably due to individual 
host immune responsiveness.  Horses that were vaccinated using the oral route also showed an 
increase in the serum IgG SeM protein antibody level post-vaccination, but not to the same 
magnitude as intranasally-vaccinated horses.  Orally-vaccinated horses also did not show evidence 
for any response in serum SeM-specific IgA following vaccination.  Horses vaccinated with 
intranasal saline did not show evidence of change in serum IgG SeM titer, serum SeM-specific 
IgA, or nasal secretion SeM-specific IgA (Figures 11, 12, and 13, respectively) from pre- to post-
vaccination indicating the source of immunologic response in experimental horses was vaccine 
administration. 
 
Figure 11:  Least square mean estimates (and corresponding 95% confidence intervals) of serum 
IgG SeM titer (Equine Diagnostic Solutions, LLC, Lexington, Kentucky) at baseline prior to 
vaccination (week 0) and 4 weeks following a 2-dose vaccine series (week 7) for horses vaccinated 
with intranasal saline.  Arrows indicate time of vaccine administration.  Intranasal saline 
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vaccination was performed at a separate time point than experimental animal vaccinations; 
therefore, direct comparison between this group and experimental animals could not be performed. 
 
 
Figure 12:  Least square mean estimates (and corresponding 95% confidence intervals) of serum 
SeM-specific IgA (in MFI) at baseline prior to vaccination (week 0) and 2 weeks following a 2-
dose vaccine series (week 5) for horses vaccinated with intranasal saline.  Arrows indicate time 
of vaccine administration.  Intranasal saline vaccination was performed at a separate time point 
than experimental animal vaccinations; therefore, direct comparison between this group and 
experimental animals could not be performed. 
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Figure 13:  Least square mean estimates (and corresponding 95% confidence intervals) of nasal 
secretion SeM-specific IgA (in MFI) at baseline prior to vaccination (week 0) and 2 weeks 
following a 2-dose vaccine series (week 5) for horses vaccinated with intranasal saline.  Arrows 
indicate time of vaccine administration.  Intranasal saline vaccination was performed at a 
separate time point than experimental animal vaccinations; therefore, direct comparison between 
this group and experimental animals could not be performed. 
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Convalescent horses have been shown to develop a strong serum IgGb response to specific 
virulence factors of S. equi, in particular surface proteins (SeM), as well as strong SeM-specific 
mucosal IgA and IgGb responses (Galan and Timoney. 1985; Sheoran et al. 1997).  Further, IgA 
in convalescent horses was first detected at 3 weeks post-challenge (Sheoran et al. 1997).  
However, neither the intranasal nor the oral routes of vaccination elicited significant changes in 
nasal secretion SeM-specific IgA response in this study.  These results contrast with those of 
Timoney (2004), who provided evidence that the attenuated intranasal S. equi vaccine induced 
both systemic and mucosal antibody responses.  Changes in mucosal antibody responses may not 
have been identified in this study because of small changes in antibody response or timing of 
sample collection (i.e. if samples were collected before detectable IgA production).  Also the 
method of nasal secretion collection used in this study may not have yielded as significant amounts 
of IgA as compared to other sampling methods like nasopharyngeal washes (Sheoran et al. 1997). 
The oral route of administration is aimed at exposing the pharyngeal tonsils to live-
attenuated bacteria, which is expected to effectively enhance local mucosal antibody expression.  
Yet, previous work has demonstrated that different routes of immunization evoke immunologic 
responses in different systems of the body (Holmgren and Czerkinsky. 2005).  Oral administration 
is known to evoke antibody responses in the intestines, mammary and salivary glands in humans; 
whereas, nasal immunization results in antibody response in the upper airway mucosa and regional 
salivary and nasal secretions (Holmgren and Czerkinsky. 2005).  A previous study evaluated oral 
administration of a killed S. equi vaccine compared to intraperitoneal administration to control 
horses after challenge (Wallace et al. 1995).  Both vaccinated groups developed submandibular 
abscesses but were not as clinically ill (i.e. did not develop fever, anorexia, malaise) as control 
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horses following challenge.  Further, horses vaccinated intraperitoneally developed IgG and IgA 
systemic and mucosal responses, but the horses vaccinated orally did not (Wallace et al. 1995).  
The oral route of administration is appealing for several practical reasons, even though it may not 
provide consistently superior immune activation and protection.  In support of the utility to this 
route, it is plausible to suggest that the lack of systemic immune activation reported by Wallace, 
et al (1995) may reflect inactivated vaccine preparation rather than the oral route of administration.   
In this investigation, no adverse effects to vaccination were found in any horses, consistent 
with other studies (Walker and Timoney. 2002; Fort Dodge Animal Health licensing report TIA 
number:  22740. 1997).  There has been work on the live-attenuated strain to remove the hasA and 
hasB genes making the microorganism acapsular and incapable of reversion to an encapsulated 
and more virulent form (Waller and Jolley. 2007; Walker and Timoney. 2002).  In a study to assess 
the safety of the vaccine used in our study, it was determined that the vaccine was safe and 
efficacious in adult horses with low antibody titers but may cause clinical disease in young, naïve 
ponies (Borst et al. 2011).  Another study evaluated adverse behavioral responses to intranasal 
vaccine administration; while horses did not show any adverse responses, a few ponies did show 
substantial adverse reactions through avoidance behavior (Grogan and McDonnell. 2005). 
On a separate note, we highlight that a novel microsphere assay was adopted here to 
measure immunologic response to S. equi vaccination.  Potential advantages of the microsphere 
assay over the standard ELISA include smaller volumes of both protein and sample that are needed 
to perform the assay, as well as the potential to multiplex the assay to measure multiple analytes 
in the same sample (Baker et al. 2012).  Thus this microsphere assay could also be modified for 
the quantitation of individual immunoglobulins (in ng/ml) in the sample, versus serum titers, which 
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may be useful for determining immunologic response to vaccination or immunologic status against 
S. equi with further development.   
 In conclusion, we identified responses in serum IgG SeM titer elicited by both intranasal 
and oral vaccination for S. equi using the USDA-approved, live-attenuated vaccine (Pinnacle IN®, 
Zoetis, Florham Park, New Jersey).  However, the magnitude of the response was considerably 
greater following the intranasal route of vaccination.  It is unknown whether the levels of serum 
IgG identified in orally vaccinated horses confer protection against S. equi.  Further work is 
warranted to definitively determine the potential utility of oral vaccination in horses. Until that 
time, manufacturer guidelines for the USDA-approved, live-attenuated S. equi vaccine (Pinnacle 
IN®, Zoetis, Florham Park, New Jersey) should be followed to ensure a maximal immune 
response. 
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Chapter 6 - Future work 
In this study, results using only MFI were analyzed.  Future work on this project would 
include optimizing an equine IgA standard curve to obtain SeM-specific IgA concentrations.  
During this project, microspheres were coated with a monoclonal mouse anti-horse IgA (AbD 
Serotec, Kidlington, United Kingdom) as described in Chapter 3: Protein coupling to magnetic 
microspheres at a concentration of 5 µg/1x106 microspheres.  A known horse reference serum 
(Bethyl Laboratorie, Inc, Montgomery, Texas) with a 1.5 mg/ml concentration of total IgA was 
diluted 1:3 to make standards of 0 ng/ml, 2.06 ng/ml, 6.17 ng/ml, 18.52 ng/ml, 55.56 ng/ml, 
166.67 ng/ml, 500 ng/ml, and 1500 ng/ml.  These microspheres were incubated with the 
secondary antibody, goat anti-horse IgA (Bethyl Laboratories Inc, Montgomery, Texas), at a 
concentration of 4 µg/ml and detection antibody, PE-conjugated donkey anti-goat IgG (Thermo 
Fisher Scientific Inc., Rockford, Illinois), at a concentration of 4 µg/ml as described in Chapter 
3: Quantitation (in MFI) of SeM protein-specific IgA.  The standard curve samples were 
analyzed by the Luminex Magpix® (LuminexCorp., Austin, Texas), and the data was analyzed 
by the Milliplex® analyst software (EMD Millipore, Billerica, Massachusetts) to generate a 
standard curve (Table 3 and Figure 14). 
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Table 3:  Data from serum with known IgA concentration (ng/ml) used to generate a standard 
curve using Milliplex® analyst software (EMD Millipore, Billerica, Massachusetts). 
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Figure 14:  Standard curve generated using Milliplex® analyst software (EMD Millipore, 
Billerica, Massachusetts) 
 
 
Dilutions of serum or nasal secretions can then be incubated with SeM protein coated 
microspheres, analyzed with the IgA standard curve samples using the Luminex Magpix® 
(LuminexCorp., Austin, Texas), and data in MFI compared to the standard curve to determine 
the SeM-specific IgA concentrations using Milliplex® analyst software (EMD Millipore, 
Billerica, Massachusetts). 
The same can be performed using an equine IgG standard curve to obtain SeM-specific 
IgG concentrations.  Microspheres can be coated with a purified anti-human IgG (Biolegend, San 
Diego, California) as described in Chapter 3: Protein coupling to magnetic microspheres at a 
concentration of 5 µg/1x106 microspheres.  A known horse reference serum (Bethyl Laboratorie, 
Inc, Montgomery, Texas) with a 14.6 mg/ml concentration of total IgG can be diluted 1:2 to 
make standards of 0 ng/ml, 1.56 ng/ml, 3.12 ng/ml, 6.25 ng/ml, 12.5 ng/ml, 25 ng/ml, 50 ng/ml, 
and 100 ng/ml as described in Chapter 2: Development of standard curves for quantitative 
measurements.  These microspheres can be incubated with the secondary antibody, biotin goat 
 48 
anti-horse IgG (Jackson ImmunoResearch Laboratories Inc, West Grove, Pennsylvania), at a 
concentration of 4 µg/ml and detection antibody, PE-conjugated donkey anti-goat IgG (Thermo 
Fisher Scientific Inc., Rockford, Illinois), at a concentration of 4 µg/ml as described in Chapter 
3: Quantitation (in MFI) of SeM protein-specific IgA.  The standard curve samples can be 
analyzed by the Luminex Magpix® (LuminexCorp., Austin, Texas), and the data analyzed by the 
Milliplex® analyst software (EMD Millipore, Billerica, Massachusetts) to generate a standard 
curve (Table 2 and Figure 1). 
In this study, a commercially-available SeM-specific IgG titer was performed to 
determine serum SeM-specific IgG.  In the future, serum SeM-specific IgG concentrations can 
be correlated to SeM-specific IgG titers to determine level of protection and need for 
vaccination.   
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